Healthcare

HOCK LOCK SIEW

As Raffles Medical celebrates its golden jubilee, the doctor calls for more patience

Growth from the group’s defensive plays in China and Vietnam will take time

Ewan Davis, partner and head of South-east Asia at Quadria Capital, says: "Healthcare really sits at the intersection of economic growth and well-being."

Privatisation of Malaysia’s Apex Healthcare a strategic fit for Quadria Capital

It is the largest such transaction in the sector in Malaysia’s history

Transformation in sectors with higher regulatory compliance will be slower if support is not tailored, say experts.
SINGAPORE BUDGET 2026

Budget 2026: AI boost a shot in the arm, but funding alone won’t drive transformation, says industry

Expanded support lowers barriers to adoption, but scaling will depend on guidance and workforce readiness

The company says its system is designed to reduce administrative burdens and make consultations more efficient, rather than replace doctors.

Jack Ma-backed Ant bets on AI health in 480 billion yuan sector race

The move comes with risks in a digital health sector littered with companies that scaled quickly, but struggled to turn a profit

Sunway Healthcare's IPO would involve 1.97 billion shares, including 575 million new shares and 1.39 billion shares from existing investors issued to retail and institutional investors.

Malaysia’s Sunway Healthcare hires six banks as IPO underwriters

Sunway plans to use the proceeds from the offering primarily to support the expansion of existing hospitals

The nation faces the second-highest burden of diabetes globally, after China, according to Lancet.

India to spend 100 billion rupees to make biopharma production hub

The funding will be directed towards the research and production of biologics and biosimilar medicines

In 2024, China’s National Medical Products Administration approved 83 new drugs, a 12% year-on-year increase, significantly outpacing the US Food and Drug Administration’s 50 novel medicines.

How China rewrote the rules of drug innovation

In an era where AI-driven drug discovery accelerates candidate generation faster than traditional systems can evaluate them, regulatory velocity becomes a binding constraint

Jay Thyagarajan, senior VP for Apac at Novo Nordisk, says that one way the company intends to manage patent expiries is through continued investments in R&D, including work on novel drug formulations.
TOPLINE

‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base

By sales volumes for its GLP-1 drugs, the company’s largest markets in the region are Australia, Japan, South Korea and India

“Investors should consider shifting from a buy-and-hold approach to more tactical strategies, rebalancing portfolios towards global opportunities," says Julius Baer's market outlook report.

Singapore a ‘safe harbour’ amid global volatility with Singdollar set to gain: Julius Baer

The wealth manager urges investors to look to growth areas for portfolio diversification